Abstracts tagged "mobile health apps"

Abstract Number: 1094 • 2019 ACR/ARP Annual Meeting
EULAR Points to Consider for the Development, Evaluation and Implementation of Mobile Health Applications for Self-management in Patients with Rheumatic and Musculoskeletal Diseases
Aurelie Najm¹, Elena Nikiphorou ², Marie Kostine ³, Christophe Richez ⁴, John Pauling ⁵, Axel Finckh ⁶, Valentin Ritschl ⁷, Petra Balazova ⁸, Simon Stones ⁹, zoltan Szekanecz ¹⁰, Yeliz Prior ¹¹, ANNAMARIA IAGNOCCO ¹², Sofia Ramiro ¹³, Francisca Sivera ¹⁴, Maxime Dougados ¹⁵, Loreto Carmona ¹⁶, Gerd Burmester ¹⁷, Dieter Wiek ¹⁸, Laure Gossec ¹⁹ and Francis Berenbaum ²⁰, ¹Nantes University Hospital, Nantes, France, ²King's College London, London, United Kingdom, ³Department of Rheumatology, Bordeaux, France, ⁴Deprtament of Rheumatology, Bordeaux, France, ⁵Department of Rheumatology, Royal National Hospital of Rheumatic Diseases, Royal United Hospitals NHS Foundation Trusts, Bath, England, United Kingdom, ⁶Division of Rheumatology, Geneva University Hospital, Switzerland, Geneva, Switzerland, ⁷Medical University of Vienna, Vienna, Austria, ⁸EULAR Young PARE, Zurich, Switzerland, ⁹University of Leeds, Leeds, United Kingdom, ¹⁰University of Debrecen, Debrecen, Hungary, ¹¹Centre for Health Sciences Research, University of Salford, Salford and Mid Cheshire NHS Foundation Trust Hospitals, Crewe, UK, Salford, United Kingdom, ¹²Academic Rheumatology Centre, Università degli Studi di Torino, TURIN, Italy, ¹³Leiden University Medical Centre, Leiden, Netherlands, ¹⁴Hospital General Universitario de Elda, Elda, Spain, ¹⁵Cochin Hospital, Paris, France, ¹⁶Instituto de Salud Musculoesquelética - Inmusc., Madrid, Spain, ¹⁷Charité—University Medicine Berlin, Berlin, Germany, ¹⁸patient research partner, Germany, Germany, Germany, ¹⁹Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ²⁰Sorbonne Université-Inserm CDR Saint-Antoine, AP-HP, Paris, France
Background/Purpose: In the expanding era of e-health, a wide range of mobile health applications (apps) have become available to enable people with rheumatic and musculoskeletal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].